Medically reviewed by Drugs.com. Last updated on Jul 21, 2022.
Patients 21 Years of Age or Younger
The recommended dose of ONCASPAR for patients up to and including 21 years of age is 2,500 International Units/m2 intramuscularly or intravenously no more frequently than every 14 days.
Premedicate patients with acetaminophen, an H-1 receptor blocker (such as diphenhydramine), and an H-2 receptor blocker (such as famotidine) 30-60 minutes prior to administration of ONCASPAR to decrease the risk and severity of both infusion and hypersensitivity reactions [see Warnings and Precautions (5.1)].
Recommended Monitoring and Dosage Modifications for Adverse Reactions
Monitor patients at least weekly, with bilirubin, transaminases, glucose and clinical examinations until recovery from the cycle of therapy. If an adverse reaction should occur, modify treatment according to Table 1.
|Infusion Reaction/Hypersensitivity Reaction [see Warnings and Precautions (5.1)]||Grade 1||
|Grade 3 to 4||
|Thrombosis [see Warnings and Precautions (5.2)]||Uncomplicated deep vein thrombosis||
|Severe or life-threatening thrombosis||
|Pancreatitis [see Warnings and Precautions (5.3)]||Grades 3 to 4||
|Hemorrhage [see Warnings and Precautions (5.5)]||Grade 3 to 4||
|Hepatotoxicity [see Warnings and Precautions (5.6)]||Total bilirubin more than 3 times to no more than 10 times the ULN||
|Total bilirubin more than 10 times the ULN||
Preparation and Administration
Administer ONCASPAR in a healthcare setting with appropriate medical support and resuscitation equipment to manage hypersensitivity reactions, should they occur [see Warnings and Precautions (5.1)].
ONCASPAR is a clear and colorless solution. Visually inspect parenteral drug products for particulate matter, cloudiness, or discoloration prior to administration. If any of these are present, discard the vial.
When ONCASPAR is administered intramuscularly:
- Limit the volume at a single injection site to 2 mL.
- If the volume to be administered is greater than 2 mL, use multiple injection sites.
When ONCASPAR is administered intravenously:
- Dilute ONCASPAR with 100 mL of 0.9% Sodium Chloride Injection, USP or 5% Dextrose Injection, USP, using aseptic technique.
- After dilution, administer immediately into a running infusion of either 0.9% Sodium Chloride, USP or 5% Dextrose Injection, USP, respectively.
- Administer over a period of 1-2 hours.
- Do not infuse other drugs through the same intravenous line during administration of ONCASPAR.
- The diluted solution should be used immediately. If immediate use is not possible, the diluted solution should be stored refrigerated at 2°C to 8°C (36°F to 46°F) for up to 48 hours. Protect infusion bags from direct sunlight.
ONCASPAR does not contain a preservative. Use only one dose per vial; discard unused product.
Frequently asked questions
More about Oncaspar (pegaspargase)
- Side effects
- Drug interactions
- During pregnancy or Breastfeeding
- Pricing & coupons
- En español
- Drug class: miscellaneous antineoplastics
Related treatment guides
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.